Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Wannhoff, Andreas [VerfasserIn]   i
 Brune, Maik [VerfasserIn]   i
 Knierim, Johannes [VerfasserIn]   i
 Weiss, Karl Heinz [VerfasserIn]   i
 Rupp, Christian [VerfasserIn]   i
 Gotthardt, Daniel [VerfasserIn]   i
Titel:Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis
Verf.angabe:Andreas Wannhoff, Maik Brune, Johannes Knierim, Karl Heinz Weiss, Christian Rupp, Daniel N. Gotthardt
E-Jahr:2019
Jahr:27 January 2019
Umfang:10 S.
Fussnoten:Gesehen am 01.04.2019
Titel Quelle:Enthalten in: Alimentary pharmacology & therapeutics
Ort Quelle:Oxford : Blackwell Science, 1987
Jahr Quelle:2019
Band/Heft Quelle:49(2019), 6, Seite 769-778
ISSN Quelle:1365-2036
Abstract:Background Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19-9 (CA19-9) can be used to screen for these malignancies. Aim To perform a longitudinal analysis of CA19-9 in patients with primary sclerosing cholangitis. Methods We conducted a retrospective analysis of CA19-9 values in patients who had primary sclerosing cholangitis, with and without biliary malignancy. We calculated the index of individuality and reference change value in patients who were cancer-free. Long-term analysis of CA19-9 in cancer-free patients was performed and we assessed the change of CA19-9 prior to diagnosis of cancer. Results We obtained 1818 CA19-9 values from 247 patients, including 32 with malignancy. Median CA19-9 in cancer-free individuals was 15.6 U/mL. The index of individuality was 0.37 and the reference change value was 46.23%. In cancer-free patients, no significant change in CA19-9 was observed at 1, 2, 5, 7, 10, 15, and 20 years after initial diagnosis of primary sclerosing cholangitis. In patients with biliary tract cancer, CA19-9 was higher at 3 months prior to diagnosis (P < 0.05) than at 6 months before diagnosis and was also higher than at 3 months prior to last follow-up in cancer-free patients (P < 0.05). In 92.9% of patients with biliary cancer, we found an increase in CA19-9 of >46.23% in the year prior to cancer diagnosis. Conclusions CA19-9 in patients with primary sclerosing cholangitis is highly individual, and the reference change value should be preferred to reference intervals. In this study, CA19-9 remained stable in patients who were cancer-free but increased early in those who developed biliary tract cancer. Regular CA19-9 measurement might improve early detection of these malignancies.
DOI:doi:10.1111/apt.15146
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1111/apt.15146
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.15146
 DOI: https://doi.org/10.1111/apt.15146
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1662607059
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68378000   QR-Code
zum Seitenanfang